Massachusetts’ largest biotech employer said in a state filing shared with the Business Journal on Friday that it would lay off workers at its Cambridge and Lexington sites. For the third time ...

For the third time this year, Takeda Pharmaceuticals Inc. has disclosed plans to lay off workers at its Cambridge and Lexington sites. Massachusetts’ largest biotech employer said in a state ...

What do Amgen, Biogen, and Takeda have in common? Leaders of research and development at the three biopharma companies shared a stage Thursday at the STAT 2024 Summit in Boston and offered their ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Takeda Pharma, Naspers and Packaging Corp. of America are part of the Zacks top Analyst Blog. OSAKA, Japan & CAMBRIDGE, Mass., September 24, 2024--Takeda (TSE:4502/NYSE:TAK) today announced that ...

Take­da will not move for­ward with Wave Life Sci­ences on a Hunt­ing­ton’s dis­ease drug, end­ing their col­lab­o­ra­tion that first start­ed in 2018 with a … ...

Wave Life Sciences (NASDAQ:WVE) said Takeda (NYSE:TAK) has elected not to exercise its option to further develop its Huntington’s disease treatment candidate WVE-003. As a result, Wave (WVE ...

Takeda is walking away from the last target in a collaboration with Wave Life Sciences into which the Japanese pharma has already sunk $260 million over the past six years. The decision leaves ...

The cytoskeleton is composed of proteins, such as tubulin. Colchicine binds to tubulin, thereby blocking the assembly and polymerization of microtubules, resulting in the suppression of leukocyte ...

Takeda took the first step away from Wave in 2021, when it paid $22.5 million to abandon the discovery research part of the deal and instead focus on clinical-stage candidates. Takeda’s decision to ...